EBSHIGH SIGNALFINANCIAL10-K

EBS achieved a dramatic turnaround from -$108.7M operating loss to $100.1M operating profit despite 29% revenue decline, while doubling cash position and significantly improving operational efficiency.

This represents a remarkable operational transformation, with the company achieving profitability through aggressive cost management (40% SG&A reduction) even as revenues contracted significantly. The dramatic improvement in operating cash flow (+191%) and doubled cash position suggests strong liquidity management, though investors should monitor whether this turnaround is sustainable given the substantial revenue decline.

Comparing 2026-02-27 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

EBS delivered an exceptional turnaround story with operating income swinging from -$108.7M loss to $100.1M profit (+192%) despite revenue falling 29% to $743M, driven by aggressive cost cutting that reduced SG&A expenses by 40% to $186M. The company dramatically improved cash generation with operating cash flow surging 191% to $170.6M and cash doubling to $205M, while reducing capital expenditures by 40%. However, the 29% revenue decline and 136% increase in interest expense to $88M raise questions about business sustainability and debt burden management despite the impressive profitability turnaround.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+192.1%
-$108.7M→$100.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+190.6%
$58.7M→$170.6M

Operating cash flow surged 190.6% — exceptional cash generation, highest quality earnings signal.

Interest Expense
P&L
+135.7%
$37.3M→$87.9M

Interest expense surged 135.7% — significant debt increase or rising rates materially impacting earnings.

Net Income
P&L
+127.6%
-$190.6M→$52.6M

Net income grew 127.6% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+106.4%
$99.5M→$205.4M

Cash position surged 106.4% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
-45.5%
$154.5M→$84.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-39.7%
$22.9M→$13.8M

Capex reduced 39.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

SG&A Expense
P&L
-39.6%
$308.0M→$186.1M

SG&A reduced 39.6% — improved cost efficiency or headcount reduction improving operating margins.

Revenue
P&L
-28.8%
$1.0B→$742.9M

Revenue softened 28.8% — monitor whether this is cyclical or structural.

R&D Expense
P&L
-24.8%
$70.7M→$53.2M

R&D spending cut 24.8% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-04
ADDED
As of February 19, 2026, the registrant had 51,770,857 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7A.
We generally identify forward-looking statements by using words like anticipate, believe, continue, could, estimate, expect, forecast, future, goal, intend, may, plan, position, possible, potential, predict, project, should, target, will, would, and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements.
All other brands, products, services and feature names or trademarks are the property of their respective owners, including KLOXXADO , which is a registered trademark of Hikma Pharmaceuticals USA Inc.
As of December 31, 2025, the Company has a portfolio of 11 products focused on addressing global public health threats like smallpox, mpox, anthrax, Ebola and opioid overdose emergencies.
+7 more — sign up free →
REMOVED
As of February 25, 2025, the registrant had 54,337,026 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 60 Item 7A.
We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements.
All other brands, products, services and feature names or trademarks are the property of their respective owners, including RSDL (Reactive Skin Decontamination Lotion), which was acquired by SERB on July 31, 2024.
As of December 31, 2024, the Company has a product portfolio of 10 products that it is actively developing and/or marketing (vaccines, therapeutics, and drug-device combination products).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →